Vacuna para el Alzheimer

EB101, developed by the EuroEspes International Center for Neuroscience and Genomic Medicine, is a model vaccine that prevents the disease and efficiently reduces brain damage in cases where Alzheimer's disease has already manifested.

¿Cómo funciona la vacuna contra el Alzhéimer?

This vaccine differs from other vaccines on the market in its dual preventive and therapeutic effect, and in the technological characteristics that make it one of the safest and most effective vaccines.

One of the differential characteristics of EB101 is that it incorporates liposomes enriched in trophic factors that give it a dual character, both preventive to avoid the onset of the disease, and therapeutic to reverse the process of neuronal death in incipient stages of the disease. Another distinguishing feature is its safety, as it has been demonstrated that it does not produce the side effects caused by other Alzheimer's vaccine prototypes, such as cerebral microhemorrhages or meningoencephalitic reactions, which led to the suspension of studies with these more primitive and unsafe vaccine models.